1666 related articles for article (PubMed ID: 27375156)
21. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
[TBL] [Abstract][Full Text] [Related]
22. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT.
Bühlmann L; Buser AS; Cantoni N; Gerull S; Tichelli A; Gratwohl A; Stern M
Bone Marrow Transplant; 2011 Oct; 46(10):1357-62. PubMed ID: 21113185
[TBL] [Abstract][Full Text] [Related]
23. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
[TBL] [Abstract][Full Text] [Related]
24. Dynamics of Torque Teno virus viremia could predict risk of complications after allogeneic hematopoietic stem cell transplantation.
Gilles R; Herling M; Holtick U; Heger E; Awerkiew S; Fish I; Höller K; Sierra S; Knops E; Kaiser R; Scheid C; Di Cristanziano V
Med Microbiol Immunol; 2017 Oct; 206(5):355-362. PubMed ID: 28702856
[TBL] [Abstract][Full Text] [Related]
25. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
26. Impact of Early Natural Killer Cell Reconstitution on the Outcomes of T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.
Zhou Z; Liu X; Zhang X; Wen S; Hua H; Wang Z; Xu Z; Lu Y; Wang F
J Inflamm Res; 2023; 16():2993-3008. PubMed ID: 37489148
[TBL] [Abstract][Full Text] [Related]
27. [Relationship between NK Cell Reconstitution and aGVHD after Allo-HSCT].
Wan LL; Chen JL; Xu C; Li BT; Hu JW; Lou X; Yang F; Liu N; Su YF; Lan SC; Wang QH; Qiao ZQ; Wang L; Jiang M; Li YH; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):530-534. PubMed ID: 28446306
[TBL] [Abstract][Full Text] [Related]
28. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
29. Real-Time PCR Analysis of Chimerism in T Cell Subsets as an Early Predictor of Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplantation.
Guz K; Nasiłowska B; Tomaszewska A; Orzińska A; Smolarczyk-Wodzyńska J; Krzemienowska M; Hałaburda K; Przybylski M; Jędrzejczak WW; Mariańska B; Brojer E
Ann Transplant; 2015 Dec; 20():720-8. PubMed ID: 26632547
[TBL] [Abstract][Full Text] [Related]
30. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
31. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
32. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
33. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
[TBL] [Abstract][Full Text] [Related]
34. Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia.
Varda-Bloom N; Danylesko I; Shouval R; Eldror S; Lev A; Davidson J; Rosenthal E; Volchek Y; Shem-Tov N; Yerushalmi R; Shimoni A; Somech R; Nagler A
Oncotarget; 2017 Jan; 8(1):418-429. PubMed ID: 27880933
[TBL] [Abstract][Full Text] [Related]
35. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
36. Early recovery of natural killer cells post T-cell depleted allogeneic stem cell transplantation using alemtuzumab "in the bag".
Davison GM; Opie JJ; Davids SFG; Mohammed R; Novitzky N
Transpl Immunol; 2024 Jun; 84():102045. PubMed ID: 38641148
[TBL] [Abstract][Full Text] [Related]
37. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
[TBL] [Abstract][Full Text] [Related]
38. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
39. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.
Jang JE; Kim SJ; Cheong JW; Hyun SY; Kim YD; Kim YR; Kim JS; Min YH
Ann Hematol; 2015 Feb; 94(2):275-82. PubMed ID: 25135450
[TBL] [Abstract][Full Text] [Related]
40. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts.
Martínez C; Urbano-Ispizua A; Rozman C; Marín P; Rovira M; Sierra J; Montfort N; Carreras E; Montserrat E
Exp Hematol; 1999 Mar; 27(3):561-8. PubMed ID: 10089920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
